This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound With the EYEOP Medical Device

This study has been completed.
Information provided by (Responsible Party):
EyeTechCare Identifier:
First received: April 15, 2011
Last updated: June 15, 2015
Last verified: March 2013
The aim of the study is to evaluate the effectiveness and the safety of the EYEOP treatment using High Intensity Focused Ultrasound in refractory glaucoma patients.

Condition Intervention
Glaucoma Device: EYEOP device

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound (HIFU). A Prospective, Multicenter, Open-label, Safety and Efficacy Study of the Treatment With the EYEOP Medical Device in Patients With Refractory Glaucoma

Resource links provided by NLM:

Further study details as provided by EyeTechCare:

Primary Outcome Measures:
  • Primary efficacy measure : [ Time Frame: 6 months ]
    IOP change (mmHg and Percent) from baseline to 6 months post-HIFU treatment

Secondary Outcome Measures:
  • Safety measures [ Time Frame: 6 months ]
    The incidence of device and procedure-related complications during the follow-up

Enrollment: 52
Study Start Date: April 2011
Study Completion Date: November 2013
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EYEOP Treatment
Open label, all subject treated by the EYEOP device
Device: EYEOP device
Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary open angle glaucoma included pseudo-exfoliative glaucoma and pigmentary glaucoma in the study eye with maximally tolerated medical treatment
  • Ocular hypertension defined as an intraocular pressure (IOP) > 21 mm Hg
  • Subject has failed a conventional intraocular glaucoma filtering surgery
  • Patient must be aged 18 years or more
  • No previous intraocular glaucoma surgery or laser treatment in the study eye during the 3 months before HIFU treatment
  • No previous cyclophotocoagulation procedure in the study eye
  • Patient able and willing to provide informed consent and to complete post-operative follow-up requirements.

Exclusion Criteria:

  • History of previous glaucoma surgery with implantation of glaucoma drainage device in the study eye
  • History of ocular or retrobulbar tumor
  • Retinal detachment, choroidal hemorrhage or detachment
  • Ocular infectious disease within 14 days before HIFU treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01338467

University Hospital
Dijon, France, 21000
University Hospital
Grenoble, France, 38000
University Hospital - Cl Huriez
Lille, France, 59000
Clinique du Parc - Private Hospital
Lyon, France, 69006
Croix Rousse Hospital
Lyon, France
XV-XX National Ophthalmologic Hospital
Paris, France, 75012
XV-XX Ophthalmologic Hospital
Paris, France, 75012
Saint-Joseph Hospital
Paris, France, 75014
Val de Grace Hospital
Paris, France, 75235
Sponsors and Collaborators
Principal Investigator: Philippe DENIS, MD Croix Rousse Hospital - Lyon - France
Study Director: Laurent FARCY EyeTechCare
Principal Investigator: Florent APTEL, MD University Hospital - Grenoble - France
  More Information

Responsible Party: EyeTechCare Identifier: NCT01338467     History of Changes
Other Study ID Numbers: EYEMUST
2011-A00196-35 ( Other Identifier: French Health Product Safety Agency (AFSSAPS) )
Study First Received: April 15, 2011
Last Updated: June 15, 2015

Keywords provided by EyeTechCare:
Refractory glaucoma
High Intensity Focused Ultrasound

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases processed this record on September 25, 2017